Balazs Halmos, Professor of Medicine at Montefiore Health System, shared on X:
“Thank you to all our highly gifted faculty and our terrific attendees along with special kudos to the tremendous PER team and wonderful co-chair Jamie Chaft to make the 21st NY Lung Cancer conference such a success!
See y’all next year on 11/13/27!”
The 21st Annual New York Lung Cancers Symposium brought together leading thoracic oncology experts from major New York metropolitan institutions and across the country on November 14, 2026. The meeting focused on translating rapidly evolving clinical trial data into practical, real-world patient care.
Key Clinical Themes and Presentations:
- EGFR-Mutated NSCLC and Shared Decision-Making. Dr. Sarah Goldberg (Yale Cancer Center) highlighted how treatment selection in frontline EGFR-mutated non–small cell lung cancer increasingly hinges on patient preferences rather than tumor characteristics alone. With three Category 1 frontline options – osimertinib monotherapy, osimertinib plus chemotherapy (FLAURA2), and amivantamab plus lazertinib (MARIPOSA) – showing comparable efficacy in combination regimens, discussions centered on balancing survival benefits against toxicity profiles and sequencing strategies after progression.
- Antibody-Drug Conjugates (ADCs) and Brain Metastases. A dedicated Medical Crossfire spotlight session moderated by Dr. Haiying Cheng examined whether novel systemic therapies, including tyrosine kinase inhibitors (TKIs) and ADCs (such as datopotamab deruxtecan and sacituzumab tirumotecan), are redefining the management of brain metastases and reducing reliance on immediate radiation.
- Multidisciplinary Tumor Boards. Interactive tumor board panels with specialists from Memorial Sloan Kettering, Mount Sinai, NYU Perlmutter, Weill Cornell, and Hofstra/Northwell dissected complex early-stage, locally advanced, and metastatic cases, integrating perspectives across medical oncology, radiation oncology, thoracic surgery, radiology, and pathology.
You can also read:
